1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2016

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 112 pages

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2016’, provides an overview of the Anaplastic Large Cell Lymphoma (ALCL) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Large Cell Lymphoma (ALCL) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Anaplastic Large Cell Lymphoma (ALCL)
- The report reviews pipeline therapeutics for Anaplastic Large Cell Lymphoma (ALCL) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anaplastic Large Cell Lymphoma (ALCL) therapeutics and enlists all their major and minor projects
- The report assesses Anaplastic Large Cell Lymphoma (ALCL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anaplastic Large Cell Lymphoma (ALCL)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anaplastic Large Cell Lymphoma (ALCL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Anaplastic Large Cell Lymphoma (ALCL) Overview 8
Therapeutics Development 9
Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) - Overview 9
Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) - Comparative Analysis 10
Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics under Development by Companies 11
Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics under Investigation by Universities/Institutes 12
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Anaplastic Large Cell Lymphoma (ALCL) - Products under Development by Companies 16
Anaplastic Large Cell Lymphoma (ALCL) - Products under Investigation by Universities/Institutes 17
Anaplastic Large Cell Lymphoma (ALCL) - Companies Involved in Therapeutics Development 18
Ariad Pharmaceuticals, Inc. 18
AstraZeneca Plc 19
Bayer AG 20
Celon Pharma Sp. z o.o. 21
Pfizer Inc. 22
Sareum Holdings Plc 23
Seattle Genetics, Inc. 24
Teva Pharmaceutical Industries Limited 25
Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
AdIL-24 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
AZD-3463 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
brentuximab vedotin - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
brigatinib - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Cellular Immunotherapy to Target CD22 for B-Cell Leukemia and Lymphoma - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
CEP-28122 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
CEP-37440 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
copanlisib hydrochloride - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
crizotinib - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Drug to Inhibit ALK for Anaplastic Large Cell Lymphoma - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
KRA-0008 - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
SAR-3 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
SAR-4 - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
SH-7129 - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
Anaplastic Large Cell Lymphoma (ALCL) - Recent Pipeline Updates 64
Anaplastic Large Cell Lymphoma (ALCL) - Dormant Projects 95
Anaplastic Large Cell Lymphoma (ALCL) - Discontinued Products 96
Anaplastic Large Cell Lymphoma (ALCL) - Product Development Milestones 97
Featured News and Press Releases 97
Jan 22, 2016: European Commission Approves Label Variation for ADCETRIS to Include Data on Retreatment of Adult Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma 97
Jun 17, 2015: Seattle Genetics Announces Multiple ADCETRIS (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma 98
Dec 07, 2014: Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting 99
Dec 06, 2014: Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting 101
Nov 07, 2014: Seattle Genetics to Present Clinical Data from Broad ADCETRIS (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014 103
Nov 06, 2014: Takeda Announces Abstracts for ADCETRIS (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma to be Presented at 56th American Society of Hematology Annual Meeting 105
Sep 24, 2014: Seattle Genetics Highlights Updated Progression-Free Survival and Overall Survival Data from ADCETRIS (Brentuximab Vedotin) Frontline PTCL Phase 1 Clinical Trial at the ESMO 2014 Congress 106
Apr 17, 2014: ADCETRIS 50mg for intravenous drip infusion", Treatment for Patients with CD30 Positive Relapsed or Refractory Hodgkin Lymphoma or Relapsed or Refractory Anaplastic Large Cell Lymphoma Now Available in Japan 107
Jan 17, 2014: Seattle Genetics Announces ADCETRIS Approval in Japan for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma 107
Jun 21, 2013: Seattle Genetics Highlights Adcetris Clinical Data At International Conference On Malignant Lymphoma 108
Appendix 111
Methodology 111
Coverage 111
Secondary Research 111
Primary Research 111
Expert Panel Validation 111
Contact Us 111
Disclaimer 112

List of Tables
Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H1 2016 9
Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL) - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016 18
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by AstraZeneca Plc, H1 2016 19
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Bayer AG, H1 2016 20
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Celon Pharma Sp. z o.o., H1 2016 21
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Pfizer Inc., H1 2016 22
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Sareum Holdings Plc, H1 2016 23
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Seattle Genetics, Inc., H1 2016 24
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2016 25
Assessment by Monotherapy Products, H1 2016 26
Number of Products by Stage and Target, H1 2016 28
Number of Products by Stage and Mechanism of Action, H1 2016 30
Number of Products by Stage and Route of Administration, H1 2016 32
Number of Products by Stage and Molecule Type, H1 2016 34
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics - Recent Pipeline Updates, H1 2016 64
Anaplastic Large Cell Lymphoma (ALCL) - Dormant Projects, H1 2016 95
Anaplastic Large Cell Lymphoma (ALCL) - Discontinued Products, H1 2016 96

List of Figures
Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H1 2016 9
Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL) - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Products, H1 2016 15
Assessment by Monotherapy Products, H1 2016 26
Number of Products by Top 10 Targets, H1 2016 27
Number of Products by Stage and Top 10 Targets, H1 2016 27
Number of Products by Top 10 Mechanism of Actions, H1 2016 29
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 29
Number of Products by Routes of Administration, H1 2016 31
Number of Products by Stage and Routes of Administration, H1 2016 31
Number of Products by Molecule Types, H1 2016 33
Number of Products by Stage and Molecule Types, H1 2016 33

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Histone ...

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) ...

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016’, ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.